title: Efficacy and Safety of Atomoxetine Hydrochloride in Asian Adults With ADHD.
abstract: The efficacy and safety of atomoxetine was assessed in adult ADHD patients from Japan, Korea, and Taiwan in this first placebo-controlled Asian clinical study in adults of an ADHD medication.
  
  
  
  Atomoxetine was compared with placebo (195 atomoxetine, 196 placebo) over 10 weeks. The change from baseline to endpoint and changes over time in the Conners' Adult ADHD Rating Scale-Investigator Rated: Screening Version total score (CAARS-Inv: SV total score) were assessed along with changes in quality of life (QoL) and executive function.
  
  
  
  Atomoxetine treatment resulted in a mean reduction of -14.3 (placebo, -8.8) in CAARS-Inv: SV total score and a steady increase of between-group differences from Week 2. Improvements in QoL and executive functioning were also observed. Treatment-emergent adverse events leading to discontinuation were infrequent (atomoxetine: 5.2%, placebo: 1.5%).
  
  
  
  Atomoxetine was tolerable and effective in improving QoL and executive function as well as ameliorating core ADHD symptoms in adult Asian patients.
authors.affiliation: 1 Eli Lilly Japan K.K., Kobe, Japan.
authors.forename: Taro
authors.initials: T
authors.lastname: Goto
authors.affiliation: 1 Eli Lilly Japan K.K., Kobe, Japan.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Hirata
authors.affiliation: 1 Eli Lilly Japan K.K., Kobe, Japan.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Takita
authors.affiliation: 2 Eli Lilly and Company, Indianapolis, IN, USA.|3 Indiana University School of Medicine, Indianapolis, IN, USA.
authors.forename: Paula T
authors.initials: PT
authors.lastname: Trzepacz
authors.affiliation: 2 Eli Lilly and Company, Indianapolis, IN, USA.
authors.forename: Albert J
authors.initials: AJ
authors.lastname: Allen
authors.affiliation: 4 Yonsei University, Seoul, Korea.
authors.forename: Dong-Ho
authors.initials: DH
authors.lastname: Song
authors.affiliation: 5 National Taiwan University, Taipei, Taiwan.
authors.forename: Susan Shur-Fen
authors.initials: SS
authors.lastname: Gau
authors.affiliation: 6 Tokyo Metropolitan Children's Medical Center, Japan.
authors.forename: Hironobu
authors.initials: H
authors.lastname: Ichikawa
authors.affiliation: 1 Eli Lilly Japan K.K., Kobe, Japan.|7 Terauchi-Takahashi Psychiatric Clinic, Ashiya, Japan.
authors.forename: Michihiro
authors.initials: M
authors.lastname: Takahashi
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D000328:Adult; D044466:Asian People / Q000208:ethnology; D000069445:Atomoxetine Hydrochloride / Q000008:administration & dosage* / Q000009:adverse effects; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000208:ethnology; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D057915:Drug Substitution; D056344:Executive Function / Q000187:drug effects; D005260:Female; D006801:Humans; D007564:Japan / Q000208:ethnology; D008297:Male; D011788:Quality of Life; D056910:Republic of Korea; D013624:Taiwan; D016896:Treatment Outcome
chemical_list: D018759:Adrenergic Uptake Inhibitors; D000069445:Atomoxetine Hydrochloride
keywords: Asian population; adult ADHD; atomoxetine; executive function; quality of life